SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Addiction Medicine Consultation — Judy Garland — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | Judy Garland |
|---|
| Date of birth | 1922-06-10 |
|---|
| Identifiers | MRN HR-ML005-SYN-TD; SSN (made up) 000-05-6127 |
|---|
| Document date | 1955-06-29 |
|---|
| Author | Tobias Grünewald, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
Long-term dependence on prescribed secobarbital and dextroamphetamine that began with pills given to her as a teenage performer, in a 33-year-old singer three months after childbirth, with depression and anxiety. Please confirm the diagnoses and advise on a safe way to withdraw the barbiturate and stop the stimulant. [S]
Urgency: Within one week, on the same day as her one-week primary care visit. [S]
Questions for the consultant:
- Does she meet criteria for sedative-hypnotic and stimulant use disorders, given that these medicines were prescribed?
- How should the barbiturate be withdrawn safely: in hospital or as an outpatient, with which medicine, and at what pace?
- Should the stimulant be stopped, and at the same time as the barbiturate or afterwards?
- How should we treat her insomnia, depression and anxiety during the taper, and what should we avoid?
- Does she need naloxone, and what monitoring do you advise?
History of Present Illness
Ms. Garland, a 33-year-old singer and actor, is seen at the request of Dr. Ellsworth-Diaz. She was given pills for energy and sleep from her early teens and has taken them ever since. For years she has taken secobarbital 200 mg at bedtime, and up to 300 mg before important days, and dextroamphetamine each morning with extra tablets on long working days. In the past week, on a single prescriber and seven-day supplies, she took 200 mg on six nights and 300 mg on one, and dextroamphetamine 10 mg each morning. She has tried to stop on her own several times and could not sleep for days. She has never had a seizure. She feels ashamed and wants to stop. She has two weeks free of performances starting next week. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Judy Garland was born Frances Ethel Gumm on June 10, 1922, in Grand Rapids, Minnesota, to parents in vaudeville, and first appeared on stage as a small child. [D]
- She was signed by Metro-Goldwyn-Mayer at 13 and became a national star at 17 in The Wizard of Oz. [D]
- As a teenage studio performer she was given stimulant "pep pills" (amphetamines; Benzedrine is named) to suppress her appetite and keep up her energy through long working days, and sleeping pills (barbiturates; Seconal is named) so that she could sleep. She later described being given pills to stay on her feet and then being put to sleep with sleeping pills at the studio hospital. [D]
- Accounts differ on who first gave her the pills. A biography by Gerald Clarke reports that her mother gave her pills for energy and sleep in early childhood, before she joined the studio; other accounts attribute the pills to the studio and its doctors. [R]
- She struggled with dependence on prescribed medicines, stimulants and sleeping pills, for the rest of her life; by her twenties she was already dependent on pills. [D]
- Suicide attempts were reported publicly, including one in 1950; a biographical encyclopedia describes others in the 1940s and early 1950s. [D]
- In her twenties she was treated for what was publicly called exhaustion and spent periods in hospitals and sanitariums, including a stay at Peter Bent Brigham Hospital in Boston in 1949. [D]
- Her contract with Metro-Goldwyn-Mayer ended in 1950, and she returned to the stage in concert. [D]
- She starred in A Star Is Born, released in 1954, and was nominated for the Academy Award for Best Actress. [D]
- She gave birth to her third child, a son, in March 1955. [D]
3 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicine | Two capsules at bedtime; no extra doses | Oral route | 1955-06-22 to 1955-07-06 | completed | S |
| Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energy | One tablet each morning | Oral route | 1955-06-22 to 1955-07-20 | completed | S |
| Sertraline 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1955-06-22 to 1955-06-29 | completed | S |
| Sertraline 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1955-06-29 | active | S |
| Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks | 150 mg intramuscularly every 13 weeks | Intramuscular route | 1955-06-22 | active | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate, with physiological dependence; began with sleeping pills given in adolescence; synthetic modern episode linked to her documented lifelong dependence on prescribed sleeping pills | active | confirmed |
F13.20 | S — Synthetic modern coding. Tolerance and withdrawal are not counted toward the diagnosis for a medicine taken under medical supervision; five other criteria are met. Person-first language; not a claim about her real diagnosis. |
| Stimulant use disorder (prescribed amphetamine), mild; began with stimulants given in adolescence for weight and energy; synthetic modern episode linked to her documented pep pills | active | confirmed |
F15.10 | S — Synthetic modern coding; DSM-5-TR mild stimulant use disorder maps to F15.10. Tolerance and withdrawal are not counted for a supervised prescription. |
| Chronic insomnia disorder, long-standing, with sleep tied to sleeping pills since adolescence | active | confirmed |
G47.00 | S — Synthetic modern diagnosis anchored to the documented sleeping pills. |
| Contraception three months after childbirth while starting an enzyme-inducing drug: injectable progestin chosen because barbiturates, including any used for the withdrawal, weaken contraceptive pills, patches, rings and implants | active | confirmed |
Z30.013 | S — Synthetic contraception need; the birth is documented. |
| Major depressive disorder, single episode, moderate, with anxious distress; Mood Disorder Questionnaire negative and no history of mania or hypomania | active | confirmed |
F32.1 | S — Synthetic modern diagnosis; not a claim about her real mood. The roster's bipolar disorder lead is not supported by the sources read and is not used. |
Physical Exam
Vital signs recorded on 1955-06-29; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| General | Alert; blood pressure 124/80, pulse 92 |
| Neurological | No tremor; no nystagmus; gait steady |
| Psychiatric | Engaged and candid; anxious; no signs of intoxication or withdrawal |
Assessment
- Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate (F13.20). Tolerance and withdrawal are not counted for a medicine taken under medical supervision. She still meets five criteria: taking more than intended, unsuccessful efforts to cut down, craving, a great deal of time spent getting prescriptions from several prescribers, and continued use despite knowing that it causes morning grogginess and worsens her low mood. That is a moderate use disorder, with physiological dependence. It began with pills given to her as a minor, and that should be said plainly to her: this is harm done to her, not a failing of hers. [S]
- Barbiturate withdrawal risk (F13.20). Daily short-acting barbiturate at 200 to 300 mg for years carries a real risk of seizures and delirium if it is stopped or cut quickly. The 1954 joint benzodiazepine tapering guideline does not cover barbiturates, but its principles apply: no abrupt stop, a long-acting agent, slow reductions she agrees to, pauses when needed, and inpatient care when severe withdrawal is likely. Phenobarbital, at about 30 mg for each 100 mg of secobarbital, is the usual long-acting substitute and should be started under supervision by clinicians experienced in its use. [S]
- Stimulant use disorder (prescribed amphetamine), mild (F15.10). Two criteria: extra doses beyond the prescription and unsuccessful efforts to cut down. No medicine is approved for stimulant use disorder, and there is no medical indication to continue it. Stopping can bring tiredness, sleepiness and low mood for a few weeks, so it should not be stopped during the barbiturate change; a short taper once phenobarbital is stable is reasonable. [S]
- Depression with anxious distress (F32.1). Sertraline is a good choice; phenobarbital may lower its level a little, so the dose should follow her response. Psychotherapy and CBT for insomnia support the taper. Avoid benzodiazepines, Z-drugs, trazodone and sedating antihistamines for sleep, which would swap one sedative for another. [S]
- Naloxone and monitoring. Naloxone reverses opioids, not barbiturates. She takes no opioid and has none in the monitoring program, and her pills all come from pharmacies, so naloxone is not needed now; it should be offered at once if an opioid is ever prescribed. Overdose risk from the barbiturate is lowered by limited supplies, locked storage, no alcohol, and the safety plan. [S]
Data reviewed: Dr. Ellsworth-Diaz's intake note, safety assessment, DAST-10 6, AUDIT-C 2, PHQ-9 14, GAD-7 13 and negative Mood Disorder Questionnaire. Prescription drug monitoring program: three prescribers and two pharmacies before intake, only this clinic since. Urine drug test at intake: barbiturates and amphetamine only. Last week's results: hemoglobin 12.3 g/dL, platelets 284, sodium 139, potassium 4.1, creatinine 0.66 mg/dL, eGFR 119, glucose 82 mg/dL, AST 21, ALT 18 and GGT 24 U/L, TSH 1.9 mIU/L, ferritin 24 ng/mL. ECG: sinus rhythm, QTc 428 ms. [S]
Plan of Treatment
- Admit for about four days to the addiction medicine service in the coming free week: stop secobarbital, start phenobarbital (starting near 30 mg three times daily), adjust with withdrawal scoring and seizure precautions, and discharge on the dose that keeps her free of withdrawal. [S]
- Then taper phenobarbital as an outpatient by no more than about 20% every two weeks, slower toward the end; pause for withdrawal symptoms, illness or a major performance; never stop abruptly. [S]
- Keep dextroamphetamine at 10 mg each morning with no extra doses until phenobarbital is stable, then 5 mg for two weeks and stop; check mood, sleep and appetite weekly for the first month. [S]
- Increase sertraline to 50 mg daily; continue psychotherapy and CBT for insomnia; no new hypnotic. [S]
- One prescriber, a monitoring program check before every prescription, supplies of one to two weeks, locked storage, take-back of unused pills, and urine drug testing after the change to phenobarbital and periodically, explained as part of care. [S]
- Medroxyprogesterone or an intrauterine device for contraception, because phenobarbital weakens pills, patches, rings and implants. [S]
- Naloxone is not needed now; reassess if an opioid is ever prescribed. [S]
- Blood count and liver tests at three to four months on phenobarbital. [S]
- Discussed with Dr. Ellsworth-Diaz, who sees her the same day. The plan was explained to Ms. Garland, who agreed and chose the dates of the admission around her work. [S]
- Follow-up: Addiction medicine team during the admission; review by video at the end of the taper or sooner if withdrawal symptoms or a return to secobarbital or a stimulant occur; Dr. Ellsworth-Diaz continues prescribing. [S]